Drugs / Methylprednisone
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06025097 | Sep 2023 | sensorineural hearing loss disorder, tinnitus | Combined Military Hospital Rawalpindi | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04791345 | Feb 2021 → Feb 2022 | — | Parc de Salut Mar | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04269850 | Sep 2019 → Nov 2024 | acute graft versus host disease | St. Petersburg State Pavlov Medical University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT00476190 | Apr 2007 → Sep 2013 | acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT00371826 | Mar 2006 → Jun 2012 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00650468 | Nov 1999 → Dec 2007 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00367562 | Jan 1996 → Dec 2005 | IgA glomerulonephritis | Hospital Britanico | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06245707 | Oct 2023 → Sep 2025 | cognitive impairment with or without cerebellar ataxia, idiopathic membranous glomerulonephritis | Beijing Friendship Hospital | Unknown | No outcome recorded |
| — | NCT01631916 | Nov 2015 → Dec 2016 | pneumonia | Hospital General de Niños Pedro de Elizalde | Withdrawn | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1/2 | NCT00968253 Background | Nov 2009 → Dec 2015 | acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02921789 Background | May 2017 → Dec 2020 | primary focal segmental glomerulosclerosis | Astellas Pharma Global Development, Inc. | Completed | Missed primary |
| Phase 2 | NCT01780844 Background | Mar 2013 → Jun 2014 | — | Astellas Pharma Global Development, Inc. | Completed | Mixed |
| Phase 2 | NCT00282308 Background | Jan 2006 → Jan 2008 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01282073 Comparator | Mar 2011 → May 2016 | membranous glomerulonephritis | Kyungpook National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01950819 Background | Dec 2013 → Feb 2017 | end stage renal failure | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT00706680 Background | Feb 2008 → Feb 2009 | diabetes mellitus, transplant rejection | University Health Network, Toronto | Unknown | No outcome recorded |
| — | NCT04568993 Comparator | Oct 2020 → Nov 2027 expected | arthropathy, trigger thumb | Sahlgrenska University Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methylprednisone | “Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.” NCT06025097 ↗16“Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet.” NCT01282073 ↗ “Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint” NCT04568993 ↗ “methyl prednisone intravenously pre-operatively, as per institutional practice.” NCT00706680 ↗ “Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day” NCT01631916 ↗ “prednisone, methylprednisone, methylprednisolone, etc.” NCT01950819 ↗ |
| Known as | SOLU-MEDROL | “Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.” NCT06025097 ↗ |
| Route | Oral | “oral 0.5 g/day of methylprednisone” NCT00367562 ↗ |